Technology ID
TAB-4532

Immunogens, Compositions, and Methods for the Treatment of Dyslipidemia

E-Numbers
E-218-2016-0
Lead Inventor
Remaley, Alan
Lead IC
NHLBI
ICs
NHLBI
Applications
Vaccines­­­
Therapeutics
Research Materials
Therapeutic Areas
Metabolic Disease
Development Stages
Pre-Clinical (in vitro)
Research Products
Antibodies

This technology includes a novel vaccine for forming autoantibodies against apoC-III, a plasma enzyme that inhibits lipolysis. The vaccine can possibly be used to treat patients with high triglycerides and are at risk for pancreatitis and cardiovascular disease. This disclosure describes an ApoC3 immunogen that includes an antigenicApoC3 peptide linked to a bacteriophage virus-like-particle (VLP) immunogenic carrier.

Commercial Applications
This vaccine has significant potential for further development as a potential therapeutic for hypertriglyceridemia.

Competitive Advantages
This technology for inducing autoantibodies against endogenous ApoC3 using peptides conjugated to virus-like-particles (VLPs) is completely novel and if successful would be a much lower cost than using antisense oligonucleotides and likely could be more widely used.

Request More Info

Licensing Contact:
Shmilovich, Michael
shmilovm@nih.gov

Patents

  • US
    Provisional (PRV) 62/340,706
    Filed on 2016-05-24
    Status: Abandoned
  • Patent Cooperation Treaty
    (PCT) PCT/US2017/034149
    Filed on 2017-05-24
    Status: Expired
  • US
    National Stage 16/304,020
    Filed on 2018-11-21
    Status: Abandoned

Collaborations

  • Licensing

Collaboration Description

  • We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.
Date Published